Quality of life, long-term survivors and long-term outcome from the ABC-02 study.

ABSTRACT:

Background

The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and provide a long-term outcome.

Methods

A total of 410 BTC patients were randomised to receive either CisGem or gemcitabine alone (Gem); 324 patients consented to complete EORTC QLQ-C30 and EORTC QLQ-PAN26 QoL questionnaires; 268 (83%) patients returned at least one QoL questionnaire (134 in each arm). Long-term survivors were defined as those surviving over 2 years and we performed a final analysis of the primary outcome; overall survival (OS).

Results

Most QoL scales showed a tre

SUBMITTER: Bridgewater J 

PROVIDER: S-EPMC4984909 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature